CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akari Therapeutics PLC (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akari Therapeutics PLC (ADR)
22 BOSTON WHARF ROAD, FL 7
Phone: (646) 350-0702p:646 350-0702 BOSTON, MA  02210  United States Ticker: AKTXAKTX

Business Summary
Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the United States Food and Drug Administration (FDA) for nomacopan for the treatment of pediatric HSCT-TMA. Additionally, the Company has a pre-clinical program developing long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202212/31/2022YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board RaymondPrudo-chlebosz 78 1/1/2023 9/18/2015
President, Chief Executive Officer, Director Rachelle S.Jacques 51 3/31/2022 3/31/2022
Interim Chief Financial Officer Wendy F.Dicicco 55 7/19/2023 7/19/2023
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Akari Malta Limited
AKTX
Celsus Therapeutics Inc.
Morria Biopharmaceuticals Plc
Morria Bopharima Ltd.
Volution Immuno Pharmaceuticals SA

General Information
Number of Employees: 15 (As of 12/31/2022)
Outstanding Shares: 7,444,917,123 (As of 12/31/2022)
Stock Exchange: NASD
Federal Tax Id: 981034922
Fax Number: (646) 843-9352


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024